IPP Bureau
Anaemia due to iron deficiency is a cause for concern in India
By IPP Bureau - December 01, 2021
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
P&G Health commemorates Iron Deficiency Day with a new Guinness World Records
By IPP Bureau - November 30, 2021
Records the largest number of videos of people saying the same sentence uploaded to Facebook in one hour to raise awareness on Iron Deficiency Anaemia
U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib
By IPP Bureau - November 30, 2021
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Galderma acquires ALASTIN Skincare to enhance its dermatology platform
By IPP Bureau - November 30, 2021
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
U.S. FDA approves Cytalux injection for identifying ovarian cancer during surgery
By IPP Bureau - November 30, 2021
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
DaVita research indicates effectiveness of mRNA vaccine in dialysis patients
By IPP Bureau - November 30, 2021
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
Conference highlights opportunities in the nursing profession
By IPP Bureau - November 30, 2021
This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year
Lupin launches learning platform for medical students
By IPP Bureau - November 30, 2021
Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their speciality
RDIF believes that Sputnik vaccines can neutralise Omicron
By IPP Bureau - November 30, 2021
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Covishield effectiveness during the second wave at 63 per cent
By IPP Bureau - November 30, 2021
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Govt reviews public health preparedness with states/UTs over Omicron
By IPP Bureau - November 30, 2021
The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases
UAE authorises Sputnik Light vaccine as universal booster
By IPP Bureau - November 30, 2021
Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE
Thermo Fisher Scientific’s new CRISPR Genome editing protein
By IPP Bureau - November 30, 2021
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
.jpg "Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy")
Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
By IPP Bureau - November 30, 2021
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
AMPATH launches its pathology laboratory in Mumbai
By IPP Bureau - November 29, 2021
The company has has 10 existing labs in India
